The Combination Therapy With Ra-223 and Enzalutamide
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Castration-resistant Prostate Cancer|Bone Metastases
DRUG: Ra-223 in combination with enzalutamide
Changes in Alkaline phosphatase (ALP), Percentage of change from baseline to 6 months (or earlier for those who discontinue study therapy), 6 months
Tolerability of Radium-223 therapy, Proportion of patients who complete 6 times injections of radium-223, 6 months|Evaluation for bone metastasis by 18F-NaF-PET, Fractional decline of intensity of tracer uptake measured by SUVmax on 18F-NaF-PET at 1, 3, 6 months., 1, 3, 6 months|Evaluation for bone metastasis by bone scintigraphy, The change of Bone Scan Index (BSI) by bone scintigraphy at 1, 3, 6 months., 1, 3, 6 months|Overall Survival Rate, Overall Survival (OS) is defined as the time from the registration to death due to any cause, or censored at date last known alive., 3 years|Time to occurrence of Symptomatic Skeletal-related Events (SSEs), Time to occurrence of SSEs are defined asthe time from registration to the date of the occurrence of SSEs (symptomatic fracture, surgery or radiation to bone, or spinal cord compression)., 1 year|Time to occurrence of visceral metastasis, Time to occurrence of visceral metastasis was defined as the time from registration to the date of the occurrence of a visceral metastasis for each patient., 1 year|Time to initiation of cytotoxic chemotherapy, The time to initiation of cytotoxic chemotherapy is defined as the time from registration to the date of initiation of cytotoxic chemotherapy., 1 year|Changes in Prostate Specific Antigen (PSA), Percent change in prostate-specific antigen (PSA) from baseline at 6 months., 6 months|Changes From Baseline for Brief Pain Inventory (BPI), The change for the BPI-SF (Brief Pain Inventory-Short Form) score was calculated., 6 months|Changes From Baseline for Functional Assessment of Cancer Therapy - Prostate (FACT-P), The change for the FACT-P TOI domain (physical and social well-being and prostate specific score) was calculated., 6 months|Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Number of participants with adverse events as a measure of safety and tolerability., 6 months
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis